About Sefacor:

---

Desaturase Interfering Lipid Complex for Solid Tumors

Initial Target: Largely de-risked for Glioblastoma (GBM) with promising clinical outcomes

SFCR001 - Sefacor’s proprietary drug for brain tumors and possibly other solid tumors - making it a pipeline in a molecule (Platform Technology for solid tumors). Drug Product ready for FDA regulatory process

HGG - High Grade Glioma (Glioblastoma Multiforme – GBM: comprises 60% of HGG)

● No effective treatment - median survival ~16 months with standard care

● ~6-7 Glioma cases per 100,000 human populations. In US: 13K GBM per year US (400K world-wide) and increasing

● SFCR001 to make a quantum leap in clinical outcomes for glioma patients; possibly a cure with modified/repeated dosing. Mutation agnostic

● GBM has seen no meaningful advances in OS or PFS. Improvement in Surgery and Radiation has hit a plateau. Effective and safe drug intervention is critical to extend or save lives. 

SFCR001:

● Not in highly fashionable/crowded areas of investigations. Validated by medical and scientific evidence

● Hypothesis: Biochemical pathways imbalanced by desaturase interference when administered at supraphysiologic concentrations; normal cells withstand these perturbations with no SAE; cancer cells cannot and die by apoptosis. Other multiple MOA proposed

● Some evidence that normal cells are protected by SFCR001 against radiation/chemo. In our animal studies, early signs of immunomodulation observed (unconfirmed)

● Academic clinical study from literature (verified by Sefacor) - API in ad hoc solution injected directly into the resected tumor bed repeatedly through a catheter. Significant clinical efficacy shown in naïve GBM/HGG patients. No adverse side effects. 80% of patients (12 of 15) and 83% of GBM patients (5 of 6) were alive and well at ~ 26 months when study ended, patients no longer followed. Two other studies on recurrent GBM patients showed efficacy and safety as well.

● A number of preclinical research studies around the globe showed efficacy/safety but no systemic development 

● All excipients are GRAS for direct brain administration

__________________________________________________________________________________________________________________________________________________________

For Investment, Partnership or Collaboration:

Contact:

Sefacor

2150 Ferncroft Lane
Chester Springs
PA 19425

Anupam Dokeniya 

adokeniya@sefacor.com

Tel: +1 617 283 2975